Key result
NPPV with pressure support yields ~3.1-fold higher odds of clinical improvement in chronic heart failure.
Why the study?
The clinical efficacy and safety of noninvasive positive pressure ventilation combined with pressure support ventilation (NPPV-PSV) in the treatment of chronic heart failure (CHF) required systematic evaluation through a meta-analysis.
Does noninvasive positive pressure ventilation combined with pressure support ventilation (NPPV-PSV) improve clinical efficacy, heart rate, respiratory rate, and oxygen saturation compared with conventional treatment alone in adults with stable chronic heart failure?
Meta-Analysis (n=568)
3 RCTs implemented blinding
4 RCTs described randomization methods in detail; 4 did not specify
Does noninvasive positive pressure ventilation combined with pressure support ventilation (NPPV-PSV) improve clinical efficacy, heart rate, respiratory rate, and oxygen saturation compared with conventional treatment alone in adults with stable chronic heart failure?
Adding noninvasive positive pressure ventilation with pressure support ventilation (NPPV-PSV) to standard medical therapy significantly improves clinical symptom efficacy, lowers heart and respiratory rates, and increases oxygen saturation in patients with stable chronic heart failure.
Answers are grounded in this paper and cite their sources.
Supports adding NPPV-PSV to standard therapy in chronic HF; confirms pooled RCT benefit on efficacy and vital signs.
OBJECTIVE: To evaluate the clinical efficacy and safety of noninvasive positive pressure ventilation combined with pressure support ventilation (NPPV-PSV) in the treatment of chronic heart failure (CHF) through a meta-analysis. METHODS: A systematic search was conducted using PubMed, Embase, Web of Science, Cochrane Library, CNKI and Wanfang databases to find randomized controlled trials and cohort studies on NPPV-PSV treatment for CHF. The period of search was set from inception until 2024. Eligible studies were included in a systematic review and meta-analysis. RESULTS: A total of 8 studies with 568 patients were included in this meta-analysis. The meta-analysis revealed that compared with conventional treatment, NPPV-PSV treatment had significant advantages in several aspects: clinical efficacy rate (total effect Z = 5.10, OR = 3.12, 95% confidence interval (CI) [2.01, 4.83], p = 0.000), heart rate (HR) (total effect Z = 16.26, MD = -10.50, 95% CI [-11.76, -9.23], p = 0.000), respiratory rate (RR) (total effect Z = 16.50, MD = -6.44, 95% CI [-7.20, -5.67], p = 0.000) and oxygen saturation (total effect Z = 12.40, MD = 0.09, 95% CI [0.08, 0.11], p = 0.000). CONCLUSION: Noninvasive positive pressure ventilation combined with PSV treatment significantly improves clinical symptoms, reduces HR and RR and increases oxygen saturation in patients with CHF, showing superior effects compared with conventional treatment.
No takes yet. Share an insight, caveat, or question.
Xiaohong Zhang (2025) conducted a meta-analysis in Chronic heart failure (CHF) (n=568). Noninvasive positive pressure ventilation combined with pressure support ventilation (NPPV-PSV) using BiPAP Vision ventilator in BiPAP mode vs. Conventional CHF treatment alone (high-flow oxygen, vasodilators, diuretics, analgesics, electrolyte balance maintenance) was evaluated on Clinical efficacy rate (disappearance or significant improvement of orthopnea, severe dyspnea, cyanosis, severe cough, pulmonary rales, and wheezing, with HR, RR, and arterial blood gas returning to near-normal levels) (OR 3.12, 95% CI 2.01-4.83, p=0.000). Noninvasive positive pressure ventilation combined with pressure support ventilation improved the clinical efficacy rate in chronic heart failure patients.
Synapse has enriched 10 related papers. Consider them for comparative context: